Skip to main content

Article Filters

Astrea Bioseparations introduces Nereus LentiHERO®, a fit-for-purpose solution for lentiviral vector purification

Published date: 28 September 2022

Back to Article Listing

First commercially available product to utilize AstreAdept, Astrea Bioseparations’ novel nanofiber-based membrane material

 Cambridge, UK, 29 September 2022: Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO® lentiviral vector (LVV) purification technology. Incorporating AstreAdept®, the Company’s proprietary nanofiber material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy.

We believe that AstreAdept will be a game-changer,explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].He added, “This launch also sets the stage for a future where cutting-edge therapies can make it into the hands of patients faster and more affordably than ever.

Despite the significant potential of LVV therapeutics, speed of development has been slow due to the lack of fit-for-purpose platforms, with users dependent on outdated and inefficient devices. To overcome these barriers, Astrea Bio is developing uniquely designed products that are easier to use than previous approaches. “High yield, combined with rapid purification are now possible by utilizing AstreAdept,explained Mr. Pizzie.

AstreAdept is a proprietary bioseparations material that utilizes cutting-edge nanofiber technology which enables biologics manufacturers to reduce process times, increase process efficiency, reduce buffer consumption, and consequently improve waste treatment costs. As a result, greener, faster, and more cost-effective bioprocessing workflows are possible.

Astrea Bio has been developing purification and separation technologies for more than 30 years, with several products used to manufacture FDA approved treatments. Nereus LentiHERO represents the first tool in the Company’s rapidly expanding toolbox of next-generation fit-for-purpose solutions for cell and gene therapy development and manufacturing.

For further information about Astrea Bioseparations, please visit: https://www.astreabioseparations.com

 FOR FURTHER INFORMATION PLEASE CONTACT:

Hannah Ingram
Head of Marketing
h.ingram@astrea-bio.com
+44 (0)1223 736 983

Your basket

Your basket is empty. Continue shopping to add products to your basket.

Search our catalogue

Call Centre

Request Quote

Please enter a valid Email AddressPlease enter a valid Email AddressThe Email Address entered is already registered, please sign in with the Email Address or enter a different one

Please enter your NamePlease enter a valid Name, the maximum length is 65 characters.

Please enter a Contact NumberPlease enter a valid Contact Number, the maximum length is 30 characters.

Please enter your company name

Please enter the quantity of products you want a quote for

Please enter the date you need these products byPlease enter a date in the format DD/MM/YYYY

Astrea Bioseparations introduces Nereus LentiHERO®, a fit-for-purpose solution for lentiviral vector purification

Published date: 28 September 2022

Back to Article Listing

First commercially available product to utilize AstreAdept, Astrea Bioseparations’ novel nanofiber-based membrane material

 Cambridge, UK, 29 September 2022: Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO® lentiviral vector (LVV) purification technology. Incorporating AstreAdept®, the Company’s proprietary nanofiber material, this novel solution addresses the challenges associated with purifying the large and fragile products used in cell and gene therapy.

We believe that AstreAdept will be a game-changer,explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].He added, “This launch also sets the stage for a future where cutting-edge therapies can make it into the hands of patients faster and more affordably than ever.

Despite the significant potential of LVV therapeutics, speed of development has been slow due to the lack of fit-for-purpose platforms, with users dependent on outdated and inefficient devices. To overcome these barriers, Astrea Bio is developing uniquely designed products that are easier to use than previous approaches. “High yield, combined with rapid purification are now possible by utilizing AstreAdept,explained Mr. Pizzie.

AstreAdept is a proprietary bioseparations material that utilizes cutting-edge nanofiber technology which enables biologics manufacturers to reduce process times, increase process efficiency, reduce buffer consumption, and consequently improve waste treatment costs. As a result, greener, faster, and more cost-effective bioprocessing workflows are possible.

Astrea Bio has been developing purification and separation technologies for more than 30 years, with several products used to manufacture FDA approved treatments. Nereus LentiHERO represents the first tool in the Company’s rapidly expanding toolbox of next-generation fit-for-purpose solutions for cell and gene therapy development and manufacturing.

For further information about Astrea Bioseparations, please visit: https://www.astreabioseparations.com

 FOR FURTHER INFORMATION PLEASE CONTACT:

Hannah Ingram
Head of Marketing
h.ingram@astrea-bio.com
+44 (0)1223 736 983

Call Centre Product Compare